Azita H Talasaz, Parham Sadeghipour, Maryam Aghakouchakzadeh, Isaac Dreyfus, Hessam Kakavand, Hamid Ariannejad, Aakriti Gupta, Mahesh V Madhavan, Benjamin W Van Tassell, David Jimenez, Manuel Monreal, Muthiah Vaduganathan, John Fanikos, Dave L Dixon, Gregory Piazza, Sahil A Parikh, Deepak L Bhatt, Gregory Y H Lip, Gregg W Stone, Harlan M Krumholz, Peter Libby, Samuel Z Goldhaber, Behnood Bikdeli
Coronavirus disease-2019 (COVID-19) is associated with systemic inflammation, endothelial activation, and multiorgan manifestations. Lipid-modulating agents may be useful in treating patients with COVID-19. These agents may inhibit viral entry by lipid raft disruption or ameliorate the inflammatory response and endothelial activation. In addition, dyslipidemia with lower high-density lipoprotein cholesterol and higher triglyceride levels portend worse outcomes in patients with COVID-19. Upon a systematic search, 40 randomized controlled trials (RCTs) with lipid-modulating agents were identified, including 17 statin trials, 14 omega-3 fatty acids RCTs, 3 fibrate RCTs, 5 niacin RCTs, and 1 dalcetrapib RCT for the management or prevention of COVID-19...
October 19, 2021: Journal of the American College of Cardiology